Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2024
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 TrialTeresa Macarulla, Zhenggang Ren, Hong Jae Chon, et al.
Blood Neoplasia|May 11, 2026
Microenvironmentally derived fatty acid-binding proteins 4 and 5 are novel therapeutic vulnerabilities in multiple myelomaHaylee Duval, Katherine Knox, Heather Fairfield, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Cancer Immunology Research|January 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial CancerMatthew D Galsky, Mark Kockx, Juliette Roels, et al.
European Urology|April 1, 2019
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate CancerWilliam S Chen, Rahul Aggarwal, Li Zhang, et al.
Nature|February 28, 2024
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T<sub>reg</sub> cellsXiangnan Guan, Ruozhen Hu, Yoonha Choi, et al.
Cell Reports. Medicine|January 27, 2024
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancerMatthew D Galsky, Xiangnan Guan, Deepali Rishipathak, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistanceJoshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Research Square|December 23, 2024
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancersBrandon M Lehrich, Evan R Delgado, Tyler M Yasaka, et al.
Pageof 4